Shots:

• Seres to receive $20M in three equal installments and have rights for targeted microbiome therapeutics for cancer immunotherapy. AZ to get an option to negotiate rights and share the development cost
• The focus of the agreement is to develop microbiome for immuno-oncology by using Seres’ expertise in microbiome with AstraZeneca’s experience in oncology products
• Seres’ leading microbiome candidates includes SER-109 & has received FDA’s BT & OD designation. SER-287 & SER-401 is currently being evaluated in P-II b & P-I b studies respectively

Ref: Seres Therapeutics | Image: AstraZeneca